Arcutis Biotherapeutics Inc. (ARQT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound
Arcutis Biotherapeutics (ARQT) is evolving into a specialized dermatology platform, leveraging ZORYVE's expanding indications, formulations, and prescriber base for compounding revenue growth. ARQT reported Q1 2026 net revenues of $105.4M (up 65% YoY), reaffirmed 2026 revenue guidance of $480–495M, and demonstrated a significant reduction in net loss with strong gross margins. ZORYVE's pediatric and primary care expansion, new product launches, and pipeline progress support ARQT's strategy to capture a larger share of the chronic dermatology market.
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.2 per share a year ago.
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ally Bridge Group NY LLC Invests $4.40 Million in Arcutis Biotherapeutics, Inc. $ARQT
Ally Bridge Group NY LLC bought a new position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) in the undefined quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 233,220 shares of the company's stock, valued at approximately $4,396,000. Arcutis Biotherapeutics accounts for approximately 2.7%
Arcutis Earnings: Zoryve Dominance And Pipeline Catalysts Drive The Bull Case
Arcutis Biotherapeutics delivered a strong Q4 2025, with $127.5M in revenue (+84% YoY) and a GAAP EPS beat, driven by Zoryve's rapid adoption. ARQT is transitioning from a launch-stage biotech to a profitable, high-growth commercial company, with Zoryve now the leading branded nonsteroidal topical in its indications. Valuation is premium at ~9x forward EV/sales but justified by operating leverage, a robust pipeline, and upcoming pediatric/label expansion catalysts.
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Q4 2025 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (ARQT) Surpasses Q4 Earnings and Revenue Estimates
Arcutis Biotherapeutics, Inc. (ARQT) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.09 per share a year ago.
Arcutis After The Double: Hypergrowth Peaks, Compounding Remains
Arcutis Biotherapeutics shifts to Hold after a 100% rally, as much of the initial de-risked growth thesis has played out. ZORYVE approvals and revenue growth have driven a fair rerating, but forward expectations now imply slower compounding and less favorable risk/reward. ARQT's long-term upside remains via steroid market conversion and pipeline optionality, yet near-term catalysts are limited and growth deceleration is expected.
Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy?
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now?
Does Arcutis Biotherapeutics, Inc. (ARQT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived
Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $1.69B estimate, supporting a bullish outlook. ARQT's Q3 net income reached $7.4M, with cash flow break-even now expected in Q4, de-risking the investment case.
